An Open-Label Phase 1/2 Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Trial Profile

An Open-Label Phase 1/2 Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Aldoxorubicin (Primary) ; Ifosfamide; Mesna
  • Indications Chondrosarcoma; Gastrointestinal stromal tumours; Osteosarcoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 08 Nov 2017 According to a CytRx Corporation media release, CytRx and NantCell executed a strategic licensing agreement for the global rights to aldoxorubicin. CytRx has been actively working with NantCell to transition the ongoing studies.
    • 02 Jun 2017 Results (n=27) assessing efficacy and toxicity presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 17 May 2017 Based on the results obtained to date, the company has decided to stop further aldoxorubicin dose escalation and continue to enroll only in the 250mg/m2 cohort.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top